#Germany #Berlin #Argent BioPharma #CannEpil #CogniCann

Argent BioPharma Expands into Germany

Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, has made a landmark advancement by entering the German pharmaceutical market. Following the successful receipt of initial purchase orders for its products CannEpil® and CogniCann®, the company is poised to harness the immense potential that Germany, as the largest healthcare market in Europe, has to offer.

This strategic expansion marks a significant commercial milestone for Argent and serves as a pivotal step in its broader European growth strategy. The recent regulatory approvals have not only permitted the sale of these innovative therapies but have also highlighted the company's commitment to improving health outcomes through advanced drug development.

In conjunction with its market entry, Argent BioPharma has also implemented a highly strategic operational realignment. The company has successfully transferred its EU GMP-certified manufacturing facilities located in Slovenia and Malta to reliable third-party operators. This transition is designed to maintain compliance with Good Manufacturing Practices (GMP) while also reducing operational overhead costs—anticipated to exceed $1 million annually. Such operational efficiencies will enable Argent to redirect capital toward enhancing its research and development initiatives and speeding up clinical trials for its core therapeutic programs.

The transformational approach adopted by Argent revolves around proprietary drug development targeting neuroimmune disorders through its established Neuro-Immune Modulatory (NIM) platform. With flagship products CannEpil®, CogniCann®, and CimetrA®, Argent is strategically positioned to enter major European markets and is on a targeted path for international growth. All these efforts are aligned with the company’s vision to deepen market penetration across high-value regions and expand its impact on global healthcare.

As the need for innovative therapeutic solutions continues to rise in Europe, Argent BioPharma's commitment to advancing its therapeutic pipeline is more crucial than ever. The company aims to leverage the ever-growing demand within the market by developing therapies that address cerebral and autoimmune disorders, which remain areas of significant unmet medical needs globally.

Moving forward, Argent BioPharma plans to prioritize the development of its existing therapeutic candidates and explore additional opportunities that may arise in Europe, aligning itself with the evolving healthcare landscape. The team is excited about the potential to make a tangible difference in patients' lives across the region with the launch of their neuroimmune products.

As they embrace this pivotal journey in Germany, Argent BioPharma continues to reinforce its dedication to innovative drug development, committed not only to maximizing growth potential but also to ensuring that the advances made translate into improved patient outcomes. The company’s entry into Germany is a testament to its operational resilience and strategic foresight, showcasing a robust model for future expansions in other key markets as it continues to shape the future of neuroimmune therapies.

Contact Information
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
Email: [email protected]

Rowan Harland
Company Secretary
+61 8 6555 2950
Email: [email protected]

For further information regarding Argent BioPharma, please visit their official website.